在前列腺癌中,PDGFC通过激活Rap1-MAPK通路,促进酶胺耐药性
Bingqian Deng1, Saipeng Chen2, Dan Zhong1
1Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Army Medical University (Third Military Medical University), Chongqing, 400038, China.
Journal of cancer research and clinical oncology
|September 24, 2025
概括
血小板衍生生长因子C (PDGFC) 通过激活信号通路,驱动前列腺癌 (PCa) 中的酶胺耐药性. 准PDGFC或其相关途径为耐药PCa提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 前列腺癌 (PCa) 是一种具有转移潜力的异质恶性瘤.
- 恩扎胺 (EnzaR) 是有效的,但抗药性不可避免地发展.
- 在PCa中产生酶胺耐药性的机制尚未完全理解.
研究的目的:
- 调查血小板衍生生长因子C (PDGFC) 在前列腺癌中对恩扎胺耐药性的作用.
- 阐明PDGFC对抗性的分子机制.
- 评估PDGFC作为抗性前列腺癌的潜在治疗标.
主要方法:
- 定量实时PCR和西部涂抹来测量PDGFC表达.
- 在体外和体内测试 (CCK8,殖民地形成,EDU,异种移植模型) 来评估PCa细胞表型.
- 露西法酶和染色质免疫沉测定以确定PDGFC的STAT4介导调节.
主要成果:
- PDGFC表达在抗恩扎胺的PCa (EnzaR PCa) 中显著升高,与增殖相关.
- 沉默PDGFC增强了EnzaRPCa细胞对恩扎胺的敏感性,抑制了细胞的进展.
- 过度表达PDGFC会以自的方式激活PDGFR-Rap1-MAPK通路.
- 单独或与酶胺一起使用的PDGFR抑制剂可以抑制异种移植的进展.
- STAT4转录因子与PDGFC促进体结合,对PDGFC进行上调.
结论:
- 在前列腺癌中,PDGFC在酶胺耐药性的发展中起着关键作用.
- 针对PDGFC或PDGFC介导的Rap1-MAPK通路代表了对EnzaR PCa.的有前途的治疗策略.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
7.2K
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.9K
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
5.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.4K
Amplifying Signals via Enzymatic Cascade
17.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
17.5K
MAPK Signaling Cascades
7.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.9K
